Search - tctmd.com

Displaying 521 - 540 of 1032

Sort: Relevancy | Date

Presentation TCT 2016

No Metallic Implants Anymore: The Case for Bioresorbable Scaffolds and ESPRIT I: Results

Presenter: Tony Das, Koen Deloose, Michael R. Jaff

October 31, 2016

Presentation TCT 2016

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Presenter: Stephen G. Ellis, Corrado Tamburino, Patrick W. Serruys

October 31, 2016

Presentation TCT 2016

Failure Modes of Bioresorbable Scaffolds: From the Obvious (Strut Thickness Considerations) to the Novel (Intraluminal Scaffold Dismantling)

Presenter: Elazer R. Edelman, Juan F. Granada

October 31, 2016

Presentation TCT 2016

Assessment and Implications of Vasomotion: Implications for BRS

Presenter: Elazer R. Edelman, Juan F. Granada, Habib Samady

October 31, 2016

Presentation TCT 2016

Benchtop Testing of BRS Mechanical Properties (General and Absorb Specific): Expansion, Recoil, Side Branches, and More

Presenter: Elazer R. Edelman, Juan F. Granada, Richard J. Rapoza

October 31, 2016

Presentation TCT 2016

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing II: Biomechanical Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing I: Pathologic Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada, Renu Virmani

October 31, 2016

Presentation TCT 2016

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

Presenter: Antonio L. Bartorelli, Kenneth Chin, Ariel Furer

October 31, 2016

Presentation TCT 2016

TCT 59: Overlapping Bioresorbable Coronary Devices: Immediate Results and Six-Month Follow-up of the REPARA Registry

Presenter: Antonio L. Bartorelli, Kenneth Chin, Felipe Hernandez

October 31, 2016

Presentation TCT 2016

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

Presenter: Michael J. Cowley, Franz-Josef Neumann, Joel Sainsous

October 31, 2016

News Industry News

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

October 31, 2016

Presentation TCT 2016

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

Presenter: Antonio L. Bartorelli, Kenneth Chin, Jens Wiebe

October 31, 2016

Presentation TCT 2016

TCT 57: Impact of Lesion Length on One-Year Outcomes of Absorb Bioresorbable Vascular Scaffolds

Presenter: Antonio L. Bartorelli, Kenneth Chin, Rony Lahoud

October 31, 2016

Presentation TCT 2016

TCT 32: Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and Four-Year Clinical and Imaging Results

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Alexandre Abizaid

October 31, 2016

Presentation TCT 2016

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Bo Xu

October 31, 2016

Presentation TCT 2016

TCT 31: Impact of Strut Thickness on Short-term Healing Response After Bioresorbable Scaffold Implantation: Serial OCT Evaluation of Novel Thin Strut Sirolimus-Eluting BRS vs Thick Strut Everolimus-Eluting BRS in Porcine Coronary Arteries

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Pawel Gasior

October 31, 2016

Presentation TCT 2016

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo

October 31, 2016

Presentation TCT 2016

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth

October 31, 2016

Presentation TCT 2016

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Michael Haude

October 31, 2016

Advertisement

No Metallic Implants Anymore: The Case for Bioresorbable Scaffolds and ESPRIT I: Results

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Failure Modes of Bioresorbable Scaffolds: From the Obvious (Strut Thickness Considerations) to the Novel (Intraluminal Scaffold Dismantling)

Assessment and Implications of Vasomotion: Implications for BRS

Benchtop Testing of BRS Mechanical Properties (General and Absorb Specific): Expansion, Recoil, Side Branches, and More

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing II: Biomechanical Perspectives

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing I: Pathologic Perspectives

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

TCT 59: Overlapping Bioresorbable Coronary Devices: Immediate Results and Six-Month Follow-up of the REPARA Registry

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

TCT 57: Impact of Lesion Length on One-Year Outcomes of Absorb Bioresorbable Vascular Scaffolds

TCT 32: Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and Four-Year Clinical and Imaging Results

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

TCT 31: Impact of Strut Thickness on Short-term Healing Response After Bioresorbable Scaffold Implantation: Serial OCT Evaluation of Novel Thin Strut Sirolimus-Eluting BRS vs Thick Strut Everolimus-Eluting BRS in Porcine Coronary Arteries

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content